Evidence map›Paper›PMID 27737686›Full record

Trial reportTrials2016

Effectiveness of a pharmacist-driven intervention in COPD (EPIC): study protocol for a randomized controlled trial.

Erin Davis, Carlo Marra, John-Michael Gamble, Jamie Farrell, Joe Lockyer, J Mark FitzGerald, Waseem Abu-Ashour, Charlie Gillis, John Hawboldt

Open access · goldAbstract readMulticenter StudyPragmatic Clinical TrialRandomized Controlled Trial
In one paragraph

Trial report in Trials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 6 pooled it
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 6 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Methods to assess COPD medications adherence in healthcare databases: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2023
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Observational
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Erin DavisMemorial University School of Pharmacy, 300 Prince Philip Dr., St. John's, NL, A1B 3V6, Canada. emdavis@mun.ca.ORCID 0000-0002-4925-1447
Carlo MarraMemorial University School of Pharmacy, 300 Prince Philip Dr., St. John's, NL, A1B 3V6, Canada.
John-Michael GambleMemorial University School of Pharmacy, 300 Prince Philip Dr., St. John's, NL, A1B 3V6, Canada.
Jamie FarrellMemorial University Faculty of Medicine, Discipline of Medicine, 300 Prince Philip Dr., St. John's, NL, A1B 3V6, Canada.
Joe LockyerMemorial University Faculty of Medicine, Discipline of Medicine, 300 Prince Philip Dr., St. John's, NL, A1B 3V6, Canada.
J Mark FitzGeraldDivision of Respiratory Medicine, The University of British Columbia, 2775 Laurel Street, Vancouver, BC, V5Z 1M9, Canada.
Waseem Abu-AshourMemorial University School of Pharmacy, 300 Prince Philip Dr., St. John's, NL, A1B 3V6, Canada.
Charlie GillisMemorial University School of Pharmacy, 300 Prince Philip Dr., St. John's, NL, A1B 3V6, Canada.
John HawboldtMemorial University School of Pharmacy, 300 Prince Philip Dr., St. John's, NL, A1B 3V6, Canada.
Memorial University of Newfoundland · CAUniversity of British Columbia · CA

Funding

CIHR
6 · The paper itself

Abstract

backgroundPatients with chronic obstructive pulmonary disease (COPD) are often nonadherent with medications and have poor inhaler technique. Community pharmacists can help to improve health-related quality of life and overall outcomes in patients with COPD. We aim to measure the effectiveness of a systematic, pharmacist-driven intervention on patients with diagnosed COPD. METHODS/

designThis pragmatic, parallel-group, cluster randomized controlled trial is designed to determine the effectiveness of a multifactorial, pharmacist-led intervention on medication adherence, inhaler technique, health-related quality of life, health care resource utilization including COPD exacerbations, and use of medications. Participating pharmacies in Newfoundland and Labrador (NL), Canada will be randomly assigned to either the intervention or the control group. The intervention group will deliver an enhanced form of care that emphasizes COPD management. The control group will provide usual care and a COPD education pamphlet. Included patients will be aged 40 years or older, have a physician-confirmed diagnosis of COPD, and be able to answer questionnaires in English. The primary outcomes are the between-group difference in the change from baseline to 6 months in medication adherence using the Medication Possession Ratio (MPR) and the Morisky Medication Adherence Scale (MMAS-8). The secondary outcomes are also measured from baseline to 6 months, and include the proportion of patients with a clinically significant change in adherence, the proportion of patients defined as having "good adherence," the mean MPR between groups, quality of life as measured by the St. George's Respiratory Questionnaire, medication inhalation technique using a pharmacist-scored checklist, health care resource utilization and antibiotic and orally administered corticosteroid use for COPD exacerbations. Differences between groups will be analyzed at the individual patient level while controlling for clustering effect. DISCUSSION: A pharmacist-led COPD intervention has the potential to improve patient medication adherence, thus increasing quality of life, possibly decreasing pulmonary exacerbations and reducing utilization of acute health care resources. Methods and results taken from this study could be used to enhance the delivery of COPD care by community pharmacists in a real-world setting. This would serve to enhance COPD population health and quality of life.

trial registrationInternational Standard Randomized Controlled Trial Number (ISRCTN) ISRCTN78138190 , registered on 3 February 2016.

Indexed as

Community Pharmacy ServicesPharmacistsAdministration, InhalationAdultBronchodilator AgentsClinical ProtocolsDelivery of Health Care, IntegratedFemaleHumansLungMaleMedication AdherenceNebulizers and VaporizersNewfoundland and LabradorPamphletsPatient Education as TopicBronchodilator AgentsChronic obstructive pulmonary diseaseCluster randomized controlled trialCommunity pharmacyMedication adherencePharmacistPharmacy practice research

Identifiers

PMID27737686
PMCPMC5064938
OpenAlexW2531894899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.